Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Congo questions Apple over knowledge of conflict minerals in its supply chainNot every WNBA draft pick will make her team's roster. Here's whyAnother exKentucky appeals court denies Bob BaffertShip comes under attack off coast of Yemen as Houthi rebel campaign appears to gain new speedMia Regan sweetly embraces Victoria Beckham as they reunite at her Mango launch event in SpainLeverkusen defender Jonathan Tah looks to finish historic season unbeaten and with more trophiesWater system from early Shang Dynasty discovered in central ChinaTravis Kelce makes shock flat earth claim, saying '10Tenerife official tells Brits looking for all
2.8795s , 6500.6640625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Chronicle news portal